Astrana Health, Inc. (ASTH) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Astrana Health, Inc. (ASTH) stock forecast summary
Our AI scores Astrana Health, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Astrana Health, Inc. is a small-cap company with a market capitalization of $1.92B. It ranks number 7 by market capitalization among the 35 Services-Management Consulting Services issuers in our coverage with a current forecast. Its Dividend Yield of 0.59% is the lowest of the 8 peers that report one.
For ASTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 51.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 38.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ASTH included.
ASTH price chart and AI forecast
How ASTH ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Astrana Health, Inc. (ASTH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Management Consulting Services peers listed below that report each metric.
Valuation & Market
| Metric | ASTH | Rank |
|---|---|---|
| Market Cap | $1.92B | 7/35 |
| P/E Ratio | 48.59x | 2/15 |
| P/B Ratio | 2.24x | 15/28 |
| Dividend Yield | 0.59% | 8/8 |
| EPS | $0.71 | – |
| Book Value/Share | $15.37 | – |
| Revenue/Share | $70.18 | – |
| FCF/Share | $1.78 | – |
Profitability & Margins
| Metric | ASTH | Rank |
|---|---|---|
| ROE | 6.2% | 11/15 |
| ROA | 2.3% | 11/19 |
| ROIC | 7.8% | 13/26 |
| Gross Margin | 10.9% | 21/22 |
| Operating Margin | 3.1% | 13/26 |
| Net Margin | 1.4% | 13/17 |
| EBT Margin | 2.2% | 15/28 |
| Tax Rate | 32.6% | – |
Financial Health
| Metric | ASTH | Rank |
|---|---|---|
| Current Ratio | 1.25x | 22/31 |
| D/E Ratio | 2.00x | 4/29 |
| Financial Leverage | 2.74x | 5/28 |
| Interest Coverage | 2.8x | 10/28 |
| Working Capital | $194M | 5/31 |
Cash Flow
| Metric | ASTH | Rank |
|---|---|---|
| Operating Cash Flow | $114M | 8/35 |
| Free Cash Flow | $99M | 7/17 |
| Capital Spending | -$15M | 10/17 |
| OCF Growth YoY | 7.2% | 5/15 |
| FCF Growth YoY | 2.5% | 3/15 |
| FCF/Sales | 2.5% | 13/17 |
| CapEx/Sales | 0.4% | 13/17 |
Operational Efficiency
| Metric | ASTH | Rank |
|---|---|---|
| Asset Turnover | 1.67x | 3/21 |
| Receivables Turnover | 7.4x | 10/19 |
| Fixed Assets Turnover | 59.2x | 7/19 |
| Days Sales Outstanding | 50 days | 10/19 |
| Payables Period | 5 days | 18/20 |
Income Statement
| Metric | ASTH | Rank |
|---|---|---|
| Total Revenue | $3.91B | 4/23 |
| Operating Income | $121M | 7/32 |
| Net Income | $53M | 8/22 |
| Cost of Goods Sold | $3.48B | 2/24 |
Dividend & Shareholder Information
| Metric | ASTH | Rank |
|---|---|---|
| Dividends Per Share | $0.20 | – |
| Payout Ratio | 28.2% | 5/7 |
| Shares Outstanding | 56M | – |
| Net Income Growth | 457.1% | 1/13 |
| EPS Growth | 22.4% | 2/12 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $980M | 41.8% of assets |
| Cash & Short-term Investments | $396M | 16.9% of assets |
| Accounts Receivable | $531M | 22.7% of assets |
| Total Liabilities | $1.71B | 73.1% of assets |
| Short-term Debt | $735M | 31.4% of assets |
ASTH quarterly financials and insider trading
Astrana Health, Inc. (ASTH) industry peers
Companies classified under the same SEC industry code as Astrana Health, Inc. (Services-Management Consulting Services): 39 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ASTH Astrana Health, Inc. | $1.92B | |
| GIB Cgi Inc | $18.33B | |
| BAH Booz Allen Hamilton Holding Corp | $10.12B | |
| G Genpact Ltd | $7.10B | |
| FCN Fti Consulting, Inc | $5.34B | |
| EXPO Exponent Inc | $4.08B | |
| HURN Huron Consulting Group Inc. | $2.77B | |
| ICFI Icf International, Inc. | $1.43B | |
| ONT Onterris, Inc. | $770M | |
| BWMN Bowman Consulting Group Ltd. | $745M | |
| RMR Rmr Group Inc. | $500M | |
| ROMA Roma Green Finance Ltd | $373M | |
| PPHC Public Policy Holding Company, Inc. | $338M | |
| HCKT Hackett Group, Inc. | $330M | |
| III Information Services Group Inc. | $287M | |
| TSSI Tss, Inc. | $168M | |
| AUC Atif Holdings Ltd | $138M | |
| PHCI Panamera Holdings Corp | $120M | |
| RTB Rtb Digital, Inc. | $83M | |
| MHH Mastech Digital, Inc. | $77M | |
| CFOR Capforce Inc. | $75M | |
| NORD Nordicus Partners Corp | $62M | |
| BLNC Balance Labs, Inc. | $52M | |
| VDTA Vertical Data Inc. | $48M | |
| EUBG Entrepreneur Universe Bright Group | $46M | |
| CTM Castellum, Inc. | $45M | |
| AERT Aeries Technology, Inc. | $29M | |
| RYOJ Ryojbaba Co., Ltd. | $27M | |
| ACCS Access Newswire Inc. | $13M | |
| GRNQ Greenpro Capital Corp. | $13M | |
| PBSV Pharma-Bio Serv, Inc. | $10M | |
| LICN Lichen International Ltd | $10M | |
| CISO Ciso Global, Inc. | $7M | |
| DFNS T3 Defense Inc. | $7M | |
| GLVT Greenlit Ventures Inc. | $60K | |
| GXXM Gex Management, Inc. | N/A | |
| IVHI Invech Holdings, Inc. | N/A | |
| SATT Sativus Tech Corp. | N/A | |
| WYGC Wenyuan Group Corp. | N/A |
Where ASTH sits on the market map
Astrana Health, Inc. (ASTH) stock news
Loading...
Astrana Health, Inc. (ASTH) stock forecast FAQ
What is the Astrana Health, Inc. (ASTH) stock forecast?
Our AI scores Astrana Health, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Astrana Health, Inc. stock predictions?
For ASTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 51.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 38.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Astrana Health, Inc. forecasts updated?
Astrana Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Astrana Health, Inc.'s industry peers?
39 issuers in our coverage, ASTH included, share the SEC industry code Services-Management Consulting Services. The largest are: Cgi Inc (GIB), Booz Allen Hamilton Holding Corp (BAH), Genpact Ltd (G), Fti Consulting, Inc (FCN), Exponent Inc (EXPO), Huron Consulting Group Inc. (HURN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.